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ABSTRACT 
A number of recent papers on the WWP2 E3 ubiquitin ligase together with two novel WWP2 
isoforms have revealed important biological insight and disease-specific functions, and also 
impacted on our understanding of ubiquitin ligases in cell cycle regulation, apoptosis and 
differentiation. Gene knockout studies suggest a developmental role for WWP2 in 
chondrogenesis via mechanisms involving cartilage-specific transcription factors. Furthermore, 
WWP2 isoforms have been shown to selectively target oncogenic signaling pathways linked to 
both the pTEN tumour suppressor and the TGFβ/Smad signaling pathway. Here, it is suggested 
that WWP2 isoforms have now emerged as central physiological regulators as well as promising 
new disease targets, and that the challenge ahead is to now develop highly selective WWP2 
inhibitors with utility in cartilage disease such as osteoarthritis and as new anticancer strategies.           
 
 
 
 
 
 
 
 
 
 
 
Protein ubiquitination represents a post-translational modification that regulates a variety 
of cellular processes including protein turnover, trafficking, sub-cellular localisation, 
transcriptional function and DNA repair mechanisms [1, 2]. Ubiquitin is a 76 amino acid protein 
and attaches covalently to target proteins via an isopeptide bond between the C-terminal Gly76 
carboxyl group on ubiquitin and the free amino group on internal lysine’s within the substrate. 
Ubiquitin conjugation involves a cascade of events catalyzed sequentially by E1 (ubiquitin-
activating), E2 (ubiquitin-conjugating), and E3 (ubiquitin ligase) enzymes. There are 
approximately 600 E3 ubiquitin ligases in the mammalian genome [3], and they are key to 
providing target substrate specificity. E3 ligases can be further sub-divided primarily into RING 
type representing around 95% of the total and HECT domain ligases, of which there are 28 
family members. The RING type E3s have no intrinsic ligase activity, and act as scaffolds that 
recruit specific substrates to an associated E2 ligase that is then responsible for ubiquitin transfer. 
In contrast, the HECT E3s have intrinsic ligase activity, and they lock onto specific substrates as 
well as directly mediating ubiquitination.  
Within the HECT E3s is a small group (9 in total) referred to as the Nedd4 superfamily. 
The Nedd4 E3s have a unique structural organization that includes the so-called HECT ligase 
catalytic domain, but also a membrane-targeting Ca2+/phospholipid-binding C2 domain and up to 
four WW (double tryptophan) domains. The WW domains interact with PPXY, phospho-Ser-Pro 
and Pro-Arg motifs and are primarily responsible for recruitment of specific target substrates. 
These unique structural and architectural features of the Nedd4 E3s not only makes an important 
contribution to their functional diversity, but also singles out this small group of E3 ligases for 
selective therapeutic targeting strategies, perhaps focused based on disrupting specific substrate 
recruitment. A similar strategy has been successfully applied to the selective cancer cell blockade 
of interactions between mdm2 ubiquitin ligase and p53 using nutlins [4].   
Whilst a number of specific substrates have been identified for individual Nedd4 family 
members [5], their normal biological as well as pathological roles remains poorly understood. 
Recently, there have been a number of reports highlighting novel functional roles for one member 
of the Nedd4 family, the WWP2 E3 ligase. Gene knockout studies reveal key developmental 
roles for WWP2 in craniofacial development [6] and chondrogenesis [7], and cell/molecular 
approaches reveal two new substrates for WWP2, pTEN [8] and Smads [9], that link to critical 
oncogenic signaling pathways responsible for cell survival and epithelial-to-mesenchymal 
transition (EMT), respectively. Furthermore, the characterization of two new isoforms generated 
from the WWP2 gene locus, WWP2-N and WWP2-C [9], highlights novel intra-molecular 
mechanisms for controlling WWP2 biological activity. 
The first WWP2 knockout mouse was recently reported by Zou et al [6], and clearly 
demonstrates an important developmental role for WWP2 in craniofacial patterning, that is likely 
to be linked to its abundant expression in cartilage tissue, and driven by the cartilage-specific 
transcription factor Sox9. Furthermore, biochemical studies identified Goosecoid (Gsc), a 
homeobox transcription factor that is already known to be important for craniofacial 
development, as a direct substrate for WWP2. In this instance, WWP2 was found to mono-
ubiquitinylate Gsc and thereby enhance its transcriptional activity, to increase expression of 
another key cartilage regulatory protein Sox6. In a separate study by Nakamura et al [7], the 
transcriptional regulation of WWP2 by Sox9 was confirmed, but WWP2 was also found to 
complex with Sox9 and encourage its transcriptional activity by facilitating its nuclear 
translocation. Once in the nucleus, WWP2 further recruits the transcription enhancer Med25 into 
to the WWP2/Sox9 complex to augment Sox9 transcriptional activity, although this activity did 
not appear to be ubiquitinylation-dependent. WWP2 is highly expressed in limb buds at E12.5 in 
mice and then in peri-articular chondrocytes at E16.5. Instead of using mouse knockouts, 
Nakamura et al [7] utilised specific morpholinos and a developing zebrafish model system, and 
again noticed defects in palatogenesis linked to aberrant cartilage function. 
Whilst both these reports highlight an important developmental role for WWP2 allied to 
cartilage and chondrocyte biology, two other recent reports suggest that WWP2 can also control 
the function of key oncogenic signalling pathways linked to cancer cell survival and tumour 
spread. PTEN is a lipid phosphatase that is frequently mutated in human cancer, and Maddika et 
al recently reported that PTEN can complex with WWP2 and undergo polubiquitinated mediated 
proteasomal turnover [8]. WWP2-mediated depletion of PTEN, which is also an important 
negative regulator of the PI3K-AKT pathway, consequently elevated AKT signalling activity and 
rendered prostate cancer cell lines resistant to stress-induced cell death. Following on from this, 
stable expression of WWP2 enhanced transformation of prostate cancer cells based soft-agar 
colony formation assays, an effect that was further supported using in vivo xenograft 
experiments.  
The oncogenic potential of WWP2 is further supported by the study of Soond and 
Chantry [9]. Here, WWP2 was found to interact with Smad proteins that are responsible for 
canonical signalling activity through the transforming growth factor-β (TGFβ) signalling 
pathway. TGFβ, acting through Smad transcription factors, has a multifunctional role in cancer 
and in late-stage tumours it is responsible for driving the differentiation programme known as 
EMT that converts static epithelial cells into highly invasive mesenchymal cells, a necessary pre-
requisite for tumour cell metastasis. Intriguingly, this study revealed for the first time two new 
isoforms generated from the WWP2 gene locus, an N-terminal WWP2-N isoform containing 
WW1 domain, and a C-terminal WWP2-C isoform harbouring WW4 domain and the HECT E3 
ligase domain. Furthermore, these isoforms displayed differentially binding activity towards 
individual Smad proteins. The full-length WWP2 (WWP2-FL) bound to TGFβ receptor regulated 
R-Smads (Smads 2/3) and also to inhibitory I-Smad7, although it has a substrate preference for I-
Smad7 which is polyubiquitinated and rapidly degraded. However, the truncated isoforms 
displayed differential binding activities, and WWP2-N bound onto Smads 2/3 selectively, 
whereas WWP2-C interacted with I-Smad7. Unexpectedly, WWP2-N, which lacks a functional 
HECT ligase domain was also found to complex with WWP2-FL in a TGFβ-regulated manner 
and activate WWP2-FL ligase activity causing degradation of unstimulated Smads 2/3. 
Consequently, it was suggested that WWP2-FL has a role to play in TGFβ-induced cancer cell 
metastasis based on its preferred substrate preference for inhibitory Smad7, and this was 
supported by cell based EMT experiments in which expression of an isolated Smad7-binding 
WW4 domain caused selective disruption of the Smad7:WWP2 complex, and stabilised Smad7 
protein levels to thereby prevent TGFβ-induced EMT. Furthermore, it was suggested that one 
role of WWP2-N might in fact be to suppress TGFβ-induced EMT, by virtue of its unique ability 
to limit the levels of receptor regulated R-Smads 2/3. Significantly, this study also highlighted for 
the first time an interdependent role for distinct WWP2 isoforms, that could impact on both the in 
vivo and cell based studies of WWP2-FL function highlighted above.  
Although from these recent studies it is clear that WWP2 is important for cartilage 
development and function, as well as being a potential proto-oncogene, it remains to be 
established how the individual WWP2 isoforms contribute to these normal biological and 
disease-specific activities. For example, the WWP2 mouse knockout was generated using a 
targeting constructs inserted into introns 3-4 of the WWP2 locus. Since the WWP2-C isoform is 
likely to be generated from an internal promoter within intron 10-11, then it is possible, although 
not confirmed, that WWP-C is still expressed in these knockout mice. Since the WWP2-C 
transcript has thus far only been detectable in cartilage-derived cell lines, then it may be that 
knockout of the WWP2-C isoform, perhaps also within the WWP2-FL-/- background, would lead 
to a more severe skeletal phenotype. In addition, factors that regulate WWP2-C promoter activity 
remain to be determined and could provide further insight into the chondrocytic-specific 
functional roles for WWP2-C isoform, particularly in the context of TGFβ/Smad signalling 
activity that is itself already known to be necessary for normal chondrocyte function [10], and is 
also implicated in major cartilage diseases such as osteoarthritis [11]. Furthermore, the WWP2-N 
isoform and its role in cartilage biology and oncogenesis warrants further investigation, 
particularly with regard to Smad regulation, but also other emerging WWP2 substrates including 
Gsc, Sox9, and PTEN, as well as the stem cell factor Oct4 [12, 13, 14]. In addition, although 
WWP2-N and WWP2-FL expression is likely to be co-regulated since they share a common 
promoter, WWP2-N is generated from a splicing event involving as yet unknown RNA splicing 
factors that leads to retention of intron 9-10 and generates a neo-transcript harbouring a 
premature stop-codon. Moreover, the utility of WWP2 and their isoforms as prognostic 
biomarkers and novel drug targets in cancer and/or cartilage diseases needs to be addressed. 
Whilst WWP2 has now stood out from the E3 ligase crowd, the challenge ahead is to capitalize 
on this functional insight and to now develop highly selective WWP2 and WWP2 isoform 
inhibitory strategies, based either on small molecule approaches against the ligase activity of 
WWP2-FL and/or WWP2-C, or selective disruption of substrate-specific WWP2 WW domain 
interactions. The 3D structure of the related WWP1 E3 ubiquitin ligase has reported and, in the 
absence of a WWP2 structure, this could be used for structure-based design approaches perhaps 
combined with high-throughput screening approaches as highlighted for the Siah2 ubiquitin 
ligase in prostate cancer [15]. Certainly, it is encouraging that recent studies now strengthen the 
case for moving forward in a similar manner with WWP2, and it’s isoforms, as promising disease 
targets in the future. 
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